Silence Therapeutics plc

NasdaqGM:SLN Stock Report

Market Cap: US$247.9m

Silence Therapeutics Past Earnings Performance

Past criteria checks 0/6

Silence Therapeutics's earnings have been declining at an average annual rate of -14.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 40.5% per year.

Key information

-14.4%

Earnings growth rate

-4.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate40.5%
Return on equity-62.3%
Net Margin-362.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%

Jan 28
Risks Still Elevated At These Prices As Silence Therapeutics plc (NASDAQ:SLN) Shares Dive 26%

Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet

Dec 10
Silence Therapeutics plc (NASDAQ:SLN) May Have Run Too Fast Too Soon With Recent 54% Price Plummet

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Silence Therapeutics wins FDA’s fast track status for blood cancer therapy

Sep 08

Silence Therapeutics prices 5.95M ADSs at $9.50/share

Aug 12

New finance chief for Silence Therapeutics

Jan 06

Revenue & Expenses Breakdown

How Silence Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:SLN Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2416-592045
30 Jun 2418-402039
31 Mar 2426-351941
31 Dec 2325-432144
30 Sep 2328-432042
30 Jun 2329-412142
31 Mar 2323-432141
31 Dec 2218-402036
30 Sep 2216-362234
30 Jun 2216-392134
31 Mar 2215-392131
31 Dec 2112-392031
30 Sep 2111-422130
30 Jun 2110-421826
31 Mar 218-351523
31 Dec 205-331420
30 Sep 203-261020
30 Jun 201-221024
31 Mar 201-211018
31 Dec 190-201013
30 Sep 190-19107
30 Jun 190-18110
31 Mar 190-18110
31 Dec 180-18110
30 Sep 180-1290
30 Jun 180-580
31 Mar 180-370
31 Dec 170-260
30 Sep 170-560
30 Jun 171-950
31 Mar 171-940
31 Dec 161-840
30 Sep 160-840
30 Jun 160-730
31 Mar 160-730
31 Dec 150-730
30 Sep 150-830
30 Jun 150-1030
31 Mar 150-1030
31 Dec 140-1130
30 Sep 140-1140
30 Jun 140-1140
31 Mar 140-1040

Quality Earnings: SLN is currently unprofitable.

Growing Profit Margin: SLN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SLN is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.

Accelerating Growth: Unable to compare SLN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).


Return on Equity

High ROE: SLN has a negative Return on Equity (-62.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 06:54
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silence Therapeutics plc is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Thomas ShraderBTIG